Chardan Capital reiterated their neutral rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research note released on Tuesday morning.

Other equities analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Regulus Therapeutics from a buy rating to a hold rating in a research note on Thursday. Wedbush reaffirmed an outperform rating and set a $4.00 price target on shares of Regulus Therapeutics in a research note on Monday, December 11th. Leerink Swann began coverage on shares of Regulus Therapeutics in a research note on Friday, January 5th. They set an outperform rating and a $2.00 price target for the company. Finally, Needham & Company LLC reaffirmed a hold rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $2.46.

Regulus Therapeutics (NASDAQ RGLS) traded up $0.01 during mid-day trading on Tuesday, hitting $1.40. 727,676 shares of the stock traded hands, compared to its average volume of 688,188. The company has a market capitalization of $144.50, a P/E ratio of -1.04 and a beta of 1.55. Regulus Therapeutics has a 12-month low of $0.79 and a 12-month high of $2.45. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.77 and a quick ratio of 6.77.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.18). Regulus Therapeutics had a negative net margin of 107,606.96% and a negative return on equity of 189.71%. sell-side analysts expect that Regulus Therapeutics will post -1.03 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. NEA Management Company LLC acquired a new stake in shares of Regulus Therapeutics during the third quarter worth $13,737,000. FMR LLC increased its position in shares of Regulus Therapeutics by 0.5% during the second quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock worth $7,862,000 after buying an additional 37,489 shares during the period. EcoR1 Capital LLC increased its position in shares of Regulus Therapeutics by 145.6% during the second quarter. EcoR1 Capital LLC now owns 3,709,144 shares of the biopharmaceutical company’s stock worth $3,656,000 after buying an additional 2,199,144 shares during the period. South Dakota Investment Council increased its position in shares of Regulus Therapeutics by 37.1% during the third quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock worth $2,275,000 after buying an additional 492,969 shares during the period. Finally, Candriam Luxembourg S.C.A. acquired a new stake in shares of Regulus Therapeutics during the third quarter worth $750,000. Institutional investors own 59.39% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Regulus Therapeutics (RGLS) Earns “Neutral” Rating from Chardan Capital” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.dailypolitical.com/2018/01/20/regulus-therapeutics-rgls-earns-neutral-rating-from-chardan-capital.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.